Are you Dr. Raghav?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Kanwal Raghav, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2006 - 2009
Delhi University College of Medical SciencesClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
OK State Medical License 2020 - 2026
TN State Medical License 2024 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Start of enrollment: 2017 Apr 07
- S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Start of enrollment: 2017 Nov 27
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Start of enrollment: 2019 Jan 29
Publications & Presentations
PubMed
- BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury
NPJ Precision Oncology. 2025-02-05 - The Landscape of ctDNA in Appendiceal Adenocarcinoma.Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, Fadl A Zeineddine, Julia Dansby
Clinical Cancer Research. 2025-02-03 - MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura
Future Oncology. 2025-02-01
Press Mentions
New Anti-HER2 Therapy Shows Promise as a Less Toxic Option for HER2+ Colorectal CancerJanuary 29th, 2025- MD Anderson Research Highlights for August 21, 2024August 21st, 2024
- Confirmed Antitumor Activity with T-dXd for HER2-Positive Metastatic CRCAugust 16th, 2024
- Join now to see all
